PT1308455E - Composicao compreendendo anticorpos anti-her2 - Google Patents

Composicao compreendendo anticorpos anti-her2

Info

Publication number
PT1308455E
PT1308455E PT02029008T PT02029008T PT1308455E PT 1308455 E PT1308455 E PT 1308455E PT 02029008 T PT02029008 T PT 02029008T PT 02029008 T PT02029008 T PT 02029008T PT 1308455 E PT1308455 E PT 1308455E
Authority
PT
Portugal
Prior art keywords
her2 antibodies
composition understanding
understanding anti
polypeptide
composition
Prior art date
Application number
PT02029008T
Other languages
English (en)
Inventor
Carol D Basey
Greg S Blank
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22185093&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1308455(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of PT1308455E publication Critical patent/PT1308455E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PT02029008T 1998-05-06 1999-05-03 Composicao compreendendo anticorpos anti-her2 PT1308455E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8445998P 1998-05-06 1998-05-06

Publications (1)

Publication Number Publication Date
PT1308455E true PT1308455E (pt) 2006-08-31

Family

ID=22185093

Family Applications (2)

Application Number Title Priority Date Filing Date
PT02029008T PT1308455E (pt) 1998-05-06 1999-05-03 Composicao compreendendo anticorpos anti-her2
PT02029009T PT1308456E (pt) 1998-05-06 1999-05-03 Purificação de anticorpos por cromatografia de permuta iónica

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT02029009T PT1308456E (pt) 1998-05-06 1999-05-03 Purificação de anticorpos por cromatografia de permuta iónica

Country Status (21)

Country Link
US (10) US6489447B1 (pt)
EP (1) EP1075488B2 (pt)
JP (6) JP4469933B2 (pt)
KR (3) KR100960211B1 (pt)
CN (6) CN1810292A (pt)
AT (2) ATE321066T1 (pt)
AU (1) AU760048B2 (pt)
BR (1) BRPI9910332B8 (pt)
CA (1) CA2329829C (pt)
CY (1) CY1107000T1 (pt)
DE (3) DE69907439T3 (pt)
DK (2) DK1308456T3 (pt)
ES (3) ES2261589T3 (pt)
GE (1) GEP20104997B (pt)
HK (2) HK1055308A1 (pt)
IL (4) IL139035A0 (pt)
NZ (1) NZ507557A (pt)
PT (2) PT1308455E (pt)
SI (1) SI1308455T1 (pt)
WO (1) WO1999057134A1 (pt)
ZA (1) ZA200005879B (pt)

Families Citing this family (269)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
PT1308455E (pt) 1998-05-06 2006-08-31 Genentech Inc Composicao compreendendo anticorpos anti-her2
ATE274522T1 (de) 1998-06-01 2004-09-15 Genentech Inc Abtrennung von antikörper-monomeren von deren multimeren mittels ionaustausch-chromatographie
US20040013667A1 (en) * 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US20030086924A1 (en) * 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
WO2001083781A2 (en) * 2000-04-28 2001-11-08 Millennium Pharmaceuticals, Inc. 14094, a novel human trypsin family member and uses thereof
US6790709B2 (en) * 2001-11-30 2004-09-14 Intel Corporation Backside metallization on microelectronic dice having beveled sides for effective thermal contact with heat dissipation devices
WO2003062375A2 (en) 2001-12-19 2003-07-31 Genentech, Inc. Stabilizing polypeptides which have been exposed to urea
FR2840695B1 (fr) * 2002-06-07 2004-10-08 Chevrillon Philippe Ind Procede de fabrication de ceintures d'impression
US7998705B2 (en) * 2002-08-06 2011-08-16 FUJIFILM Diosynth Biotechnologies U.S.A., Inc Increased dynamic binding capacity in ion exchange chromatography by addition of polyethylene glycol
AU2003265994B2 (en) 2002-09-11 2010-04-01 Genentech, Inc. Protein purification
PL1648998T3 (pl) * 2003-07-18 2015-03-31 Amgen Inc Specyficzne czynniki wiążące czynnik wzrostu hepatocytów
US8244358B2 (en) 2003-10-15 2012-08-14 Rmx, Llc Device and method for treating obstructive sleep apnea
US7979128B2 (en) 2003-10-15 2011-07-12 Rmx, Llc Device and method for gradually controlling breathing
US8467876B2 (en) 2003-10-15 2013-06-18 Rmx, Llc Breathing disorder detection and therapy delivery device and method
US8140164B2 (en) 2003-10-15 2012-03-20 Rmx, Llc Therapeutic diaphragm stimulation device and method
US8160711B2 (en) 2003-10-15 2012-04-17 Rmx, Llc Multimode device and method for controlling breathing
US8265759B2 (en) 2003-10-15 2012-09-11 Rmx, Llc Device and method for treating disorders of the cardiovascular system or heart
US7970475B2 (en) 2003-10-15 2011-06-28 Rmx, Llc Device and method for biasing lung volume
US9259573B2 (en) 2003-10-15 2016-02-16 Rmx, Llc Device and method for manipulating exhalation
LT2380911T (lt) 2003-11-05 2018-07-10 Roche Glycart Ag Antigeną surišančios molekulės, pasižyminčios padidintu fc receptoriaus surišimo afiniškumu ir efektoriaus funkcija
ZA200607435B (en) 2004-02-06 2009-05-27 Pharmatel Red Pty Ltd As The T Use of aminosalicylates in diarrhoea-predominant irritable bowel syndrome
US20060234907A1 (en) * 2004-02-13 2006-10-19 Werner Gehringer Albumin solution and process for the production thereof
US7713629B2 (en) 2004-03-26 2010-05-11 Florida State University Research Foundation Hydrophobic fluorinated polyelectrolyte complex films and associated methods
US9056125B2 (en) 2004-05-17 2015-06-16 Florida State University Research Foundation, Inc. Films for controlled cell growth and adhesion
SV2006002143A (es) * 2004-06-16 2006-01-26 Genentech Inc Uso de un anticuerpo para el tratamiento del cancer resistente al platino
KR20180091967A (ko) 2004-07-22 2018-08-16 제넨테크, 인크. Ｈｅｒ２ 항체 조성물
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
RU2007125644A (ru) * 2004-12-07 2009-01-20 Дженентек Инк. (Us) Отбор пациентов для терапии ингибитором her
CN101141981A (zh) 2005-01-21 2008-03-12 健泰科生物技术公司 Her抗体的固定剂量给药
RU2007133660A (ru) * 2005-02-09 2009-03-20 Дженентек, Инк. (Us) Ингибирование шеддинга her2 антагонистами матриксной металлопротеиназы
EP2399605A1 (en) 2005-02-23 2011-12-28 Genentech, Inc. Extending time to disease progression or survival in cancer patients
US7585955B2 (en) * 2005-03-03 2009-09-08 Florida State University Research Foundation, Inc Protein separation from a protein mixture
TW200642695A (en) * 2005-03-08 2006-12-16 Genentech Inc Methods for identifying tumors responsive to treatment with her dimerization inhibitors (HDIs)
US7459542B2 (en) * 2005-03-10 2008-12-02 Florida State University Research Foundation, Inc. Separation of albumin from protein samples
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
TWI391399B (zh) 2005-05-25 2013-04-01 Hoffmann La Roche 測定溶離多肽之鹽濃度之方法
PE20070207A1 (es) 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
US7452872B2 (en) 2005-08-24 2008-11-18 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
US8921344B2 (en) 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
NZ611859A (en) * 2006-04-05 2014-12-24 Abbvie Biotechnology Ltd Antibody purification
AU2007321877B2 (en) * 2006-08-01 2011-11-03 Kineta Two, Llc Pharmaceutical manufacturing methods
KR101770312B1 (ko) 2006-08-28 2017-08-22 아레스 트레이딩 에스.에이. Ｆｃ­함유 단백질을 정제하는 방법
US20100267932A1 (en) * 2006-08-28 2010-10-21 Alex Eon-Duval Process for the purification of fc-fusion proteins
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
KR20090074040A (ko) 2006-09-13 2009-07-03 아보트 러보러터리즈 세포 배양의 개선
US8280513B2 (en) 2006-12-22 2012-10-02 Rmx, Llc Device and method to treat flow limitations
EP2120915B1 (en) * 2007-01-22 2011-09-28 Genentech, Inc. Polyelectrolyte precipitation and purification of antibodies
WO2008109440A2 (en) 2007-03-02 2008-09-12 Genentech, Inc. Predicting response to a her dimerisation inhibitor based on low her3 expression
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
CN101679509A (zh) * 2007-06-01 2010-03-24 弗·哈夫曼-拉罗切有限公司 免疫球蛋白纯化
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
CA3006428A1 (en) 2007-06-08 2008-12-18 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
AU2012227163B2 (en) * 2007-10-30 2015-07-16 Genentech, Inc. Antibody purification by cation exchange chromatography
ES2666170T3 (es) 2007-10-30 2018-05-03 Genentech, Inc. Purificación de anticuerpos mediante cromatografía de intercambio catiónico
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
CA2711256C (en) 2008-01-03 2019-01-15 The Scripps Research Institute Antibody targeting through a modular recognition domain
TWI472339B (zh) * 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
ES2545977T3 (es) 2008-03-18 2015-09-17 Genentech, Inc. Combinaciones de un conjugado de anticuerpo-fármaco anti-HER2 y agentes quimioterapéuticos, y métodos de uso
CA2722466A1 (en) 2008-04-29 2009-11-05 Tariq Ghayur Dual variable domain immunoglobulins and uses thereof
WO2009149189A2 (en) 2008-06-03 2009-12-10 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
TW201006485A (en) 2008-06-03 2010-02-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
EP2318832B1 (en) 2008-07-15 2013-10-09 Academia Sinica Glycan arrays on ptfe-like aluminum coated glass slides and related methods
LT2848625T (lt) 2008-08-14 2019-10-10 Genentech, Inc. Priemaišų pašalinimo būdai, panaudojant reziduojančio baltymo pakeitimą jonų mainų membraninės chromatografijos pagalba
TW201014605A (en) 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
AU2008221604B2 (en) * 2008-09-22 2010-04-22 Commonwealth Scientific And Industrial Research Organisation Temperature-responsive polymer particles in protein separation applications
EP3524620A1 (en) 2008-10-14 2019-08-14 Genentech, Inc. Immunoglobulin variants and uses thereof
SG10201702951RA (en) 2008-10-20 2017-06-29 Abbvie Inc Viral inactivation during purification of antibodies
SG10201702922VA (en) 2008-10-20 2017-06-29 Abbvie Inc Isolation and purification of antibodies using protein a affinity chromatography
RU2553214C2 (ru) 2008-10-29 2015-06-10 Аблинкс Н.В. Способы очистки однодоменных антигенсвязывающих молекул
EP2400984A4 (en) * 2009-02-25 2013-01-23 Merck Sharp & Dohme HER2 ANTIBODY COMPOSITIONS
KR20130080871A (ko) 2009-03-20 2013-07-15 제넨테크, 인크. 이중특이적 항-ｈｅｒ 항체
US8481694B2 (en) * 2009-04-29 2013-07-09 Bio-Rad Laboratories, Inc. Purification of immunoconjugates
CN102421448A (zh) 2009-05-29 2012-04-18 霍夫曼-拉罗奇有限公司 Her2信号传导调控剂在表达her2的胃癌患者中
SG177727A1 (en) 2009-07-24 2012-02-28 Hoffmann La Roche Stirrer system
US20120177640A1 (en) 2009-07-24 2012-07-12 Josef Burg Optimizing the production of antibodies
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
EP2467399B2 (en) * 2009-08-20 2023-02-01 Baxalta Incorporated Purification of vWF for increased removal of non-lipid enveloped viruses
AU2010289527C1 (en) 2009-09-01 2014-10-30 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
KR101508044B1 (ko) 2009-10-01 2015-04-07 에프. 호프만-라 로슈 아게 다단계 최종 여과
EP2488658A4 (en) 2009-10-15 2013-06-19 Abbvie Inc IMMUNOGLOBULINE WITH DOUBLE VARIABLE DOMAIN AND ITS USE
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
US8304248B2 (en) * 2009-11-16 2012-11-06 Torres Anthony R Protein separation via ion-exchange chromatography and associated methods, systems, and devices
US8697844B2 (en) * 2009-11-24 2014-04-15 Novo Nordisk A/S Method of purifying pegylated proteins
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
AR079256A1 (es) * 2009-12-04 2012-01-04 Genentech Inc Metodo para el tratamiento del cancer de mama metastasico con trastuzumab-mcc-dm1
CA2781682A1 (en) 2009-12-04 2011-06-09 Genentech, Inc. Multispecific antibodies, antibody analogs, compositions, and methods
PT3272764T (pt) 2009-12-18 2024-04-24 Novartis Ag Método para cromatografia de afinidade
SI2536748T1 (sl) 2010-02-18 2014-12-31 Genentech, Inc. Nevrogulinski antagonisti in njihova uporaba pri zdravljenju raka
US10338069B2 (en) 2010-04-12 2019-07-02 Academia Sinica Glycan arrays for high throughput screening of viruses
KR101152036B1 (ko) 2010-04-27 2012-06-08 (주)셀트리온 컬럼 순환 및 시료 연속주입법을 이용한 단백질 ａ 크로마토그래피 정제 방법
AU2011250970B2 (en) 2010-05-10 2016-12-15 Sinica, Academia Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
SG185601A1 (en) * 2010-05-18 2012-12-28 Abbvie Inc Apparatus and process of purification of proteins
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
CN102905718A (zh) * 2010-05-25 2013-01-30 弗·哈夫曼-拉罗切有限公司 纯化多肽的方法
RU2604811C2 (ru) 2010-05-27 2016-12-10 Мерк Шарп Энд Домэ Корп. Способ получения антител с улучшенными свойствами
WO2012009705A1 (en) 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
GB201012603D0 (en) 2010-07-27 2010-09-08 Ucb Pharma Sa Protein purification
BR112013002578A2 (pt) 2010-08-03 2019-05-14 Abbvie Inc. imunoglobinas de domínio variável duplo e usos das mesmas
NZ604510A (en) 2010-08-17 2013-10-25 Csl Ltd Dilutable biocidal compositions and methods of use
TW201211252A (en) 2010-08-26 2012-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
US20130230869A1 (en) * 2010-09-01 2013-09-05 National Cancer Center Antibody against colorectal cancer marker
CA2809632A1 (en) 2010-10-05 2012-04-12 Monika Baehner Antibodies against human tweak and uses thereof
JP6023715B2 (ja) * 2010-10-11 2016-11-09 アッヴィ・バハマズ・リミテッド タンパク質の精製方法
EP2643353A1 (en) 2010-11-24 2013-10-02 Novartis AG Multispecific molecules
SG191071A1 (en) * 2010-12-08 2013-07-31 Amgen Inc Ion exchange chromatography in the presence of an amino acid
EP2655412B1 (en) 2010-12-21 2018-01-17 F. Hoffmann-La Roche AG Isoform enriched antibody preparation and method for obtaining it
JP5766296B2 (ja) 2010-12-23 2015-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
WO2012117120A1 (en) * 2011-03-03 2012-09-07 Arla Foods Amba Method for isolating osteopontin using concentrated feeds
US9624294B2 (en) 2011-03-14 2017-04-18 Cellmid Limited Antibody recognizing N-domain of midkine
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
WO2012162561A2 (en) 2011-05-24 2012-11-29 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
BR112013031943B1 (pt) 2011-06-13 2021-10-13 Csl Limited Composição que compreende proteínas e anticorpos contra g-csfr
BR112014003431A2 (pt) 2011-08-17 2017-06-13 Genentech Inc anticorpo, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, agente farmacêutico, uso do anticorpo, método de tratamento de um indivíduo que tem câncer e método de aumento de tempo para recorrência de tumor
EP2764020B1 (en) 2011-10-05 2015-08-12 F. Hoffmann-La Roche AG Process for antibody g1 glycoform production
CN104334189A (zh) 2011-10-14 2015-02-04 霍夫曼-拉罗奇有限公司 Her2二聚化抑制剂帕妥珠单抗的用途和包含her2二聚化抑制剂帕妥珠单抗的制品
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
EP2771351B1 (en) 2011-10-28 2017-06-14 Patrys Limited Pat-lm1 epitopes and methods for using same
WO2013066707A1 (en) * 2011-10-31 2013-05-10 Merck Sharp & Dohme Corp. Chromatography process for resolving heterogeneous antibody aggregates
CA2854330A1 (en) * 2011-11-02 2013-05-10 Genentech, Inc. Overload and elute chromatography
AU2012346540C1 (en) 2011-11-30 2019-07-04 Genentech, Inc. ErbB3 mutations in cancer
EP2788500A1 (en) 2011-12-09 2014-10-15 F.Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
WO2013096812A1 (en) 2011-12-23 2013-06-27 Genentech, Inc. Articles of manufacture and methods for co-administration of antibodies
WO2013102042A2 (en) 2011-12-30 2013-07-04 Abbvie Inc. Dual specific binding proteins directed against il-13 and/or il-17
BR112014024017A8 (pt) 2012-03-27 2017-07-25 Genentech Inc Métodos de tratamento de um tipo de câncer, de tratamento do carcinoma, para selecionar uma terapia e para quantificação e inibidor de her3
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9505833B2 (en) 2012-04-20 2016-11-29 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
SG11201408161RA (en) 2012-06-08 2015-01-29 Sutro Biopharma Inc Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
ES2611788T3 (es) * 2012-06-26 2017-05-10 Sutro Biopharma, Inc. Proteínas de Fc modificadas que comprenden residuos de aminoácidos no naturales específicos del sitio, conjugados de las mismas, métodos para su preparación y métodos para su uso
US9914956B2 (en) 2012-08-18 2018-03-13 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
AU2013305827A1 (en) 2012-08-21 2015-03-05 Academia Sinica Benzocyclooctyne compounds and uses thereof
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US9206390B2 (en) 2012-09-02 2015-12-08 Abbvie, Inc. Methods to control protein heterogeneity
RU2017137740A (ru) 2012-11-01 2019-02-11 Эббви Инк. Анти-vegf/dll4-иммуноглобулины с двойными вариабельными доменами и их применения
CN104813168B (zh) 2012-11-30 2017-10-20 霍夫曼-拉罗奇有限公司 需要pd‑l1抑制剂综合疗法的患者的鉴定
WO2014118685A2 (en) * 2013-01-29 2014-08-07 Dr. Reddy's Laboratories Limited Method of altering the acidic variant content of antibody
EP4219552A3 (en) 2013-02-07 2023-09-13 CSL Ltd. Il-11r binding proteins and uses thereof
SG10201709131UA (en) 2013-03-08 2017-12-28 Genzyme Corp Continuous purification of therapeutic proteins
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
SG11201505901YA (en) 2013-03-14 2015-08-28 Emd Millipore Corp Methods of increasing protein purity using protein a based chromatography
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
CA2907181C (en) 2013-03-15 2023-10-17 Viktor Roschke Multivalent and monovalent multispecific complexes and their uses
EP2970459A2 (en) 2013-03-15 2016-01-20 AbbVie Inc. Dual specific binding proteins directed against il-1beta and il-17
NZ751877A (en) 2013-04-16 2020-04-24 Genentech Inc Pertuzumab variants and evaluation thereof
TWI596107B (zh) 2013-06-25 2017-08-21 卡地拉保健有限公司 單株抗體之新穎純化方法
US10086054B2 (en) 2013-06-26 2018-10-02 Academia Sinica RM2 antigens and use thereof
US9981030B2 (en) 2013-06-27 2018-05-29 Academia Sinica Glycan conjugates and use thereof
WO2015006555A2 (en) 2013-07-10 2015-01-15 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
KR102251127B1 (ko) 2013-07-12 2021-05-11 제넨테크, 인크. 이온 교환 크로마토그래피 입력 최적화의 설명
US9782476B2 (en) 2013-09-06 2017-10-10 Academia Sinica Human iNKT cell activation using glycolipids with altered glycosyl groups
EP3048109A4 (en) * 2013-09-17 2017-04-19 Kaneka Corporation Novel antibody purification method and antibody obtained therefrom, and novel antibody purification method using cation exchanger and antibody obtained therefrom
EP3052640A2 (en) 2013-10-04 2016-08-10 AbbVie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
SG10201811186XA (en) * 2013-10-18 2019-01-30 Novasep Process Purification of proteins
US10351592B2 (en) * 2013-10-30 2019-07-16 Celltrion, Inc. Method for separating antibody isoforms using cation exchange chromatography
CN104628846B (zh) * 2013-11-06 2019-12-06 三生国健药业（上海）股份有限公司 重组蛋白质的纯化方法
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
KR20160104727A (ko) 2014-01-16 2016-09-05 아카데미아 시니카 암의 치료 및 검출을 위한 조성물 및 방법
TWI709570B (zh) 2014-01-17 2020-11-11 美商健臻公司 無菌層析法及製法
TWI709569B (zh) 2014-01-17 2020-11-11 美商健臻公司 無菌層析樹脂及其用於製造方法的用途
EP3129767B1 (en) 2014-03-27 2021-09-01 Academia Sinica Reactive labelling compounds and uses thereof
CA2946860A1 (en) 2014-04-25 2015-10-29 Genentech, Inc. Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab
EP3149037A4 (en) 2014-05-27 2018-01-10 Academia Sinica Anti-her2 glycoantibodies and uses thereof
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
EP3149036A4 (en) 2014-05-27 2017-12-27 Academia Sinica Anti-cd20 glycoantibodies and uses thereof
KR20170005142A (ko) 2014-05-27 2017-01-11 아카데미아 시니카 증진된 항체 효능을 위한 범용 당형태에 관한 조성물 및 방법
JP7063538B2 (ja) 2014-05-28 2022-05-09 アカデミア シニカ 抗ＴＮＦα糖操作抗体群およびその使用
TW201617360A (zh) * 2014-06-25 2016-05-16 桂格 史考特 布蘭克 用於純化蛋白質之方法及試劑
CN105315369B (zh) * 2014-07-25 2020-03-13 山东博安生物技术有限公司 利用阳离子交换层析纯化蛋白质
WO2016033245A1 (en) 2014-08-26 2016-03-03 Rmx, Llc Devices and methods for reducing intrathoracic pressure
TWI745275B (zh) 2014-09-08 2021-11-11 中央研究院 使用醣脂激活人類ｉＮＫＴ細胞
JP2021006540A (ja) * 2014-09-10 2021-01-21 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ガラクトース操作型免疫グロブリン１抗体
CN106687481B (zh) 2014-09-10 2022-03-22 豪夫迈·罗氏有限公司 半乳糖改造的免疫球蛋白1抗体
SI3191135T1 (sl) 2014-09-12 2021-01-29 Genentech, Inc. Anti-HER2 protitelesa in imunokonjugati
BR112017004953A2 (pt) 2014-09-17 2017-12-05 Genentech Inc imunoconjugado, formulação farmacêutica, método de tratamento e método de inibição da proliferação de uma célula
WO2016061632A1 (en) 2014-10-23 2016-04-28 La Trobe University Fn14-binding proteins and uses thereof
PL3215528T3 (pl) 2014-11-06 2020-01-31 F.Hoffmann-La Roche Ag Warianty regionu Fc ze zmodyfikowanym wiązaniem FcRn i sposoby stosowania
KR101531479B1 (ko) * 2014-11-21 2015-06-26 세원셀론텍(주) 의료용 재료로 사용하기 위한 고농도 콜라겐 제조방법
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
US10940212B2 (en) 2014-12-19 2021-03-09 Monash University IL-21 agonist antibodies and methods of treatment using same
CN105820251B (zh) * 2015-01-08 2019-10-15 江苏康宁杰瑞生物制药有限公司 具有共同轻链的双特异性抗体或抗体混合物
EP3242685B1 (en) 2015-01-09 2022-05-04 AdAlta Limited Cxcr4 binding molecules
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
EP3247718B1 (en) * 2015-01-21 2021-09-01 Outlook Therapeutics, Inc. Modulation of charge variants in a monoclonal antibody composition
AU2015378564A1 (en) 2015-01-24 2017-07-13 Academia Sinica Novel glycan conjugates and methods of use thereof
WO2016149088A1 (en) * 2015-03-13 2016-09-22 Bristol-Myers Squibb Company Use of alkaline washes during chromatography to remove impurities
EP3302551B1 (en) 2015-05-30 2024-06-26 F. Hoffmann-La Roche AG Methods of treating her2-positive previously untreated metastatic breast cancer
TW201709934A (zh) 2015-06-15 2017-03-16 建南德克公司 抗體及免疫結合物
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
HUE044139T2 (hu) 2015-07-07 2019-09-30 Hoffmann La Roche Kombinált terápia egy HER2-ellenes antitest-gyógyszer konjugátummal és bcl-2 inhibitorral
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
JP2018537458A (ja) * 2015-11-18 2018-12-20 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 改善されたタンパク質分離のための逆ｐＨ塩勾配
AU2016355739A1 (en) * 2015-11-18 2018-07-05 Merck Patent Gmbh Improved protein separation in ion exchange chromatography
KR20180104106A (ko) 2016-01-27 2018-09-19 서트로 바이오파마, 인크. anti-CD74 항체 접합체, anti-CD74 항체 접합체를 포함하는 조성물 및 anti-CD74 항체 접합체의 이용 방법
CN109563161A (zh) 2016-02-03 2019-04-02 安口生物公司 用于提高抗体稳定性的缓冲制剂
CA3016170A1 (en) 2016-03-08 2017-09-14 Academia Sinica Methods for modular synthesis of n-glycans and arrays thereof
US20190151346A1 (en) 2016-05-10 2019-05-23 INSERM (Institute National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer
EP3484911B1 (en) * 2016-07-15 2020-11-04 H. Hoffnabb-La Roche Ag Method for purifying pegylated erythropoietin
CA3034057A1 (en) 2016-08-22 2018-03-01 CHO Pharma Inc. Antibodies, binding fragments, and methods of use
US11498977B2 (en) 2016-09-29 2022-11-15 Beijing Hanmi Pharmaceutical Co., Ltd. Heterodimeric immunoglobulin constructs and preparation methods thereof
WO2018085513A1 (en) 2016-11-04 2018-05-11 Genentech, Inc. Treatment of her2-positive breast cancer
EP3533804A4 (en) * 2016-11-18 2020-06-17 Beijing Hanmi Pharmaceutical Co., Ltd. BISPECIFIC ANTIBODY TYPE ANTI-PD -1 / ANTI-HER2 NATURAL ANTIBODY HETERODIMERIC FORM AND PREPARATION THEREOF
US20180221481A1 (en) 2016-12-28 2018-08-09 Genentech, Inc. Treatment of advanced her2 expressing cancer
CA3047349C (en) 2017-01-17 2020-09-22 Genentech, Inc. Subcutaneous her2 antibody formulations
RS65204B1 (sr) 2017-03-02 2024-03-29 Genentech Inc Adjuvansni tretman her2-pozitivnog raka dojke
WO2018200505A1 (en) 2017-04-24 2018-11-01 Genentech, Inc. Erbb2/her2 mutations in the transmbrane or juxtamembrane domain
CN107602702A (zh) * 2017-09-22 2018-01-19 生标（上海）医疗器械科技有限公司 一种同时靶向人p185和血管内皮生长因子的抗体及其应用
CN108101987A (zh) * 2017-11-17 2018-06-01 安徽未名生物医药有限公司 一种重组抗TNF-α全人源单克隆抗体的纯化方法
CA3081770A1 (en) 2017-11-29 2019-06-06 Csl Limited Method of treating or preventing ischemia-reperfusion injury
WO2019153200A1 (zh) 2018-02-08 2019-08-15 北京韩美药品有限公司 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备
MX2020009512A (es) 2018-03-13 2020-10-22 Hoffmann La Roche Terapia de combinacion con agonistas de 4-ibb (cd137) direccionados.
CN111954678A (zh) 2018-04-02 2020-11-17 美国安进公司 厄瑞努单抗组合物及其用途
EP3774900A1 (en) 2018-04-13 2021-02-17 F. Hoffmann-La Roche AG Her2-targeting antigen binding molecules comprising 4-1bbl
WO2020047345A1 (en) 2018-08-31 2020-03-05 Yale University Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators
BR112021003420A2 (pt) 2018-08-31 2021-05-18 Genzyme Corporation resina cromatográfica estéril e uso da mesma em processos de manufatura
LT3856774T (lt) 2018-10-15 2023-03-10 F. Hoffmann-La Roche Ag Liekamojo krūties vėžio gydymo trastuzumabo emtanzinu būdai
CN111196856A (zh) * 2018-11-19 2020-05-26 三生国健药业（上海）股份有限公司 抗her2/pd1双特异性抗体
EP3952996A1 (en) 2019-04-12 2022-02-16 F. Hoffmann-La Roche AG Bispecific antigen binding molecules comprising lipocalin muteins
WO2020234742A1 (en) 2019-05-20 2020-11-26 Lupin Limited Granulocyte colony stimulating factor purification
WO2020252294A1 (en) 2019-06-13 2020-12-17 Bolt Biotherapeutics, Inc. Aminobenzazepine compounds, immunoconjugates, and uses thereof
US11266838B1 (en) 2019-06-21 2022-03-08 Rmx, Llc Airway diagnostics utilizing phrenic nerve stimulation device and method
CN110339209B (zh) * 2019-07-18 2023-06-06 上海泰坦科技股份有限公司 一种去甲状腺结合蛋白的小牛血清的制备方法
JP2022546110A (ja) 2019-09-03 2022-11-02 ボルト バイオセラピューティクス、インコーポレーテッド アミノキノリン化合物、免疫複合体、及びそれらの使用
JP2022549510A (ja) 2019-09-30 2022-11-25 ボルト バイオセラピューティクス、インコーポレーテッド アミド結合したアミノベンズアゼピン免疫複合体、及びその使用
EP4045917A1 (en) * 2019-10-14 2022-08-24 Pierce Biotechnology, Inc. Peptide purification formulations and methods
BR112022007719A2 (pt) 2019-10-25 2022-07-12 Bolt Biotherapeutics Inc Imunoconjugados, composto ligante, composição farmacêutica, método para tratar câncer, uso de um imunoconjugado e método de preparação de um imunoconjugado
EP4058024A1 (en) 2019-11-15 2022-09-21 Seagen Inc. Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate
US11725048B2 (en) 2019-12-20 2023-08-15 Hudson Institute of Medical Research CXCL10 binding proteins and compositions thereof
CA3176626A1 (en) 2020-05-08 2021-11-11 David Dornan Elastase-substrate, peptide linker immunoconjugates, and uses thereof
WO2021259890A1 (en) 2020-06-23 2021-12-30 F. Hoffmann-La Roche Ag Agonistic cd28 antigen binding molecules targeting her2
AU2020456731A1 (en) 2020-06-29 2023-01-05 F. Hoffmann-La Roche Ag Pertuzumab plus trastuzumab fixed dose combination
KR20230037560A (ko) 2020-07-14 2023-03-16 에프. 호프만-라 로슈 아게 고정 용량 조합에 대한 분석
WO2022013613A2 (en) 2020-07-17 2022-01-20 Onena Medicines S.L. Antibodies against lefty proteins
CN116234586A (zh) 2020-08-13 2023-06-06 博尔特生物治疗药物有限公司 吡唑并氮呯免疫缀合物及其用途
CN112430252B (zh) * 2020-11-13 2022-09-02 宜昌东阳光长江药业股份有限公司 一种提高目标蛋白回收率的层析方法
EP4259211A1 (en) 2020-12-11 2023-10-18 Bolt Biotherapeutics, Inc. Anti-her2 immunoconjugates, and uses thereof
CA3204489A1 (en) 2020-12-11 2022-06-16 Genentech, Inc. Combination therapies for treatment of her2 cancer
JP2023552792A (ja) 2020-12-11 2023-12-19 ボルト バイオセラピューティクス、インコーポレーテッド 抗ｈｅｒ２免疫複合体、及びその使用
CA3212926A1 (en) 2021-03-26 2022-09-29 Gary Brandt 2-amino-4-carboxamide-benzazepine immunoconjugates, and uses thereof
US20240197899A1 (en) 2021-03-26 2024-06-20 Bolt Biotherapeutics, Inc. 2-amino-4-carboxamide-benzazepine immunoconjugates, and uses thereof
CA3215602A1 (en) 2021-04-01 2022-10-06 Vestaron Corporation Av3 mutant polypeptides for pest control
CN113769794B (zh) * 2021-07-06 2024-04-05 沁浩膜技术(厦门)有限公司 一种连续脱除胞磷胆碱钠中杂质的离子交换***及方法
WO2023076599A1 (en) 2021-10-29 2023-05-04 Bolt Biotherapeutics, Inc. Tlr agonist immunoconjugates with cysteine-mutant antibodies, and uses thereof
WO2023122805A1 (en) 2021-12-20 2023-06-29 Vestaron Corporation Sorbitol driven selection pressure method
CN114230641B (zh) * 2021-12-29 2024-03-26 内蒙古必威安泰生物科技有限公司 一种去除***抗原液中内毒素的方法
WO2023192924A1 (en) 2022-03-30 2023-10-05 Vestaron Corporation Combinations of av3 mutant polypeptides and bt toxins for pest control
WO2023225555A1 (en) 2022-05-18 2023-11-23 Vestaron Corporation Pesticidal actx peptide variants
WO2023245100A1 (en) 2022-06-17 2023-12-21 Vestaron Corporation Antimicrobial ncr13 variant peptides
WO2024026406A2 (en) 2022-07-29 2024-02-01 Vestaron Corporation Next Generation ACTX Peptides
WO2024038183A1 (en) 2022-08-18 2024-02-22 Immunocore Limited Multi-domain binding molecules
WO2024038193A1 (en) 2022-08-18 2024-02-22 Immunocore Limited Multi-domain binding molecules
WO2024038198A1 (en) 2022-08-18 2024-02-22 Immunocore Limited Multi-domain binding molecules

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3070041D1 (en) * 1979-12-13 1985-03-07 Ciba Geigy Ag Optical brighteners from bistyryl benzene, process for their preparation and their use
US4511213A (en) * 1981-12-24 1985-04-16 Kokusai Denshin Denwa Kabushiki Kaisha Coding method for multilevel-gradated picture signal
US5169774A (en) * 1984-02-08 1992-12-08 Cetus Oncology Corporation Monoclonal anti-human breast cancer antibodies
US6054561A (en) * 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
US4753894A (en) * 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
WO1986002068A1 (en) * 1984-09-26 1986-04-10 Takeda Chemical Industries, Ltd. Mutual separation of proteins
US5196323A (en) * 1985-04-27 1993-03-23 Boehringer Ingelheim International Gmbh Process for preparing and purifying alpha-interferon
US5525338A (en) * 1992-08-21 1996-06-11 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin conjugates
CA1283072C (en) * 1986-12-01 1991-04-16 Timothy Durance Process for the isolation and separation of lysozyme and avidin from eggwhite
EP0289129A3 (en) † 1987-03-26 1990-10-10 Repligen Corporation High purity protein a preparation
CA1339946C (en) * 1987-03-31 1998-07-07 Michael J. Griffith Ultrapurification process for polypeptides
US5451662A (en) * 1987-10-23 1995-09-19 Schering Corporation Method of purifying protein
US5118796A (en) 1987-12-09 1992-06-02 Centocor, Incorporated Efficient large-scale purification of immunoglobulins and derivatives
JP3040121B2 (ja) † 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
IT1219874B (it) 1988-03-18 1990-05-24 Fidia Farmaceutici Utilizzazione del fattore di crescita nervoso umano e sue composizioni farmaceutiche
US5115101A (en) * 1988-06-08 1992-05-19 Miles Inc. Removal of protein A from antibody preparations
US5112951A (en) * 1989-07-28 1992-05-12 Hybritech Incorporated Separation of anti-metal chelate antibodies
US5177194A (en) * 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
US5110913A (en) * 1990-05-25 1992-05-05 Miles Inc. Antibody purification method
JP4124480B2 (ja) * 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
EP0861893A3 (en) 1991-09-19 1999-11-10 Genentech, Inc. High level expression of immunoglobulin polypeptides
JPH05202098A (ja) 1992-01-29 1993-08-10 Snow Brand Milk Prod Co Ltd 乳質原料から生理活性物質の製造法
US5279823A (en) * 1992-06-08 1994-01-18 Genentech, Inc. Purified forms of DNASE
EP0656788B1 (en) * 1992-08-07 2006-10-18 Pharmexa Inc. Hla binding peptides and their uses
DK38293D0 (da) † 1993-03-31 1993-03-31 Novo Nordisk As Fremstilling af proteiner
DK0659767T4 (da) * 1993-12-27 2003-02-10 Zlb Bioplasma Ag Fremgangsmåde til fremstilling af et koncentrat af anti-D-immunoglobulin G og et farmaceutisk præparat, som indeholder dette
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
DE4436910A1 (de) * 1994-10-15 1996-04-18 Behringwerke Ag Regenerierbare Festphase zur Durchführung spezifischer Bindereaktionen
GB9423454D0 (en) * 1994-11-21 1995-01-11 Allied Colloids Ltd Deinking processes and novel polymers for use in these
US5641870A (en) * 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
IL118201A (en) 1995-05-11 2004-12-15 Roche Diagnostics Gmbh Preparation comprising a protein with human erythropoietin activity which is free of serum and non-recombinant mammalian protein and process for the preparation thereof
US5714583A (en) † 1995-06-07 1998-02-03 Genetics Institute, Inc. Factor IX purification methods
EP1516628B1 (en) * 1995-07-27 2013-08-21 Genentech, Inc. Stable isotonic lyophilized protein formulation
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
JPH1042892A (ja) * 1996-08-01 1998-02-17 Higeta Shoyu Co Ltd タンパク質の回収精製法
NZ335207A (en) * 1996-11-15 2000-09-29 Genentech Inc Process to isolate recombinant human neurotrophin using hydrophobic chromatography resin
ES2337091T3 (es) * 1996-11-27 2010-04-20 Genentech, Inc. Purificacion por afinidad de polipeptido en una matriz de proteina.
DE19724054C2 (de) 1997-06-07 2002-09-12 Braun Gmbh Strahlungsthermometer und Schutzkappe dafür
PT1308455E (pt) 1998-05-06 2006-08-31 Genentech Inc Composicao compreendendo anticorpos anti-her2
WO2002029045A2 (en) 2000-10-02 2002-04-11 Novo Nordisk A/S Method for the production of vitamin k-dependent proteins
WO2004083421A1 (en) 2003-03-18 2004-09-30 Novo Nordisk Health Care Ag Method for the production of gla-residue containing serine proteases

Also Published As

Publication number Publication date
ES2198913T5 (es) 2013-11-18
DE69930424D1 (de) 2006-05-11
HK1055307A1 (en) 2004-01-02
SI1308455T1 (sl) 2006-08-31
JP2016028060A (ja) 2016-02-25
PT1308456E (pt) 2007-12-03
CY1107000T1 (el) 2012-09-26
IL173183A0 (en) 2006-06-11
JP5836905B2 (ja) 2015-12-24
AU3877799A (en) 1999-11-23
WO1999057134A1 (en) 1999-11-11
DK1308456T3 (da) 2007-12-27
GEP20104997B (en) 2010-06-10
US9249218B2 (en) 2016-02-02
DE69936946T2 (de) 2008-05-15
KR101036414B1 (ko) 2011-05-23
US20030078388A1 (en) 2003-04-24
JP4469933B2 (ja) 2010-06-02
US7074404B2 (en) 2006-07-11
ATE370961T1 (de) 2007-09-15
DK1075488T4 (da) 2013-10-21
EP1075488B2 (en) 2013-08-07
US20060182739A1 (en) 2006-08-17
EP1075488A1 (en) 2001-02-14
CN101333244B (zh) 2013-12-18
DE69907439D1 (de) 2003-06-05
AU760048B2 (en) 2003-05-08
DK1075488T3 (da) 2003-08-18
JP2017149721A (ja) 2017-08-31
CN1626547A (zh) 2005-06-15
US6489447B1 (en) 2002-12-03
CN1305896C (zh) 2007-03-21
HK1055308A1 (en) 2004-01-02
KR20010043323A (ko) 2001-05-25
IL173183A (en) 2013-11-28
CN1260249C (zh) 2006-06-21
IL139035A (en) 2006-10-31
CN103641885A (zh) 2014-03-19
JP2018140994A (ja) 2018-09-13
CN1299370A (zh) 2001-06-13
DE69930424T2 (de) 2006-12-14
NZ507557A (en) 2003-10-31
CA2329829A1 (en) 1999-11-11
ES2198913T3 (es) 2004-02-01
ES2261589T3 (es) 2006-11-16
KR20100017967A (ko) 2010-02-16
KR100960211B1 (ko) 2010-05-27
DE69907439T2 (de) 2004-04-01
CN100404547C (zh) 2008-07-23
US20160376377A1 (en) 2016-12-29
IL139035A0 (en) 2001-11-25
BR9910332A (pt) 2001-09-25
US7531645B2 (en) 2009-05-12
BRPI9910332B8 (pt) 2021-05-25
ES2292682T3 (es) 2008-03-16
CA2329829C (en) 2012-10-16
CN101333244A (zh) 2008-12-31
BRPI9910332B1 (pt) 2016-10-25
ZA200005879B (en) 2001-10-22
DE69936946D1 (de) 2007-10-04
US6339142B1 (en) 2002-01-15
US20050063972A1 (en) 2005-03-24
KR20060081422A (ko) 2006-07-12
CN1626548A (zh) 2005-06-15
CN1810292A (zh) 2006-08-02
JP2010106023A (ja) 2010-05-13
JP2013032365A (ja) 2013-02-14
JP5133962B2 (ja) 2013-01-30
ATE321066T1 (de) 2006-04-15
IL228987A0 (en) 2013-12-31
US20140018523A1 (en) 2014-01-16
JP2002513800A (ja) 2002-05-14
US20170226224A1 (en) 2017-08-10
EP1075488B1 (en) 2003-05-02
US20090220492A1 (en) 2009-09-03
DE69907439T3 (de) 2014-01-02
US6417335B1 (en) 2002-07-09

Similar Documents

Publication Publication Date Title
PT1308455E (pt) Composicao compreendendo anticorpos anti-her2
EP1308456A3 (en) Antibody purification by ion exchange chromatography
ATE425989T1 (de) Proteinreinigungsverfahren
MX9603637A (es) Purificacion de anticuerpo.
WO2004024866A3 (en) Protein purification
MX9707909A (es) Purificacion de anticuerpos.
DE502005007091D1 (de) Verfahren zur reinigung von erythropoietin
DE69430016D1 (de) Proteinreinigung
ATE278705T1 (de) Verfahren zur reinigung von proteinen
KR940005284A (ko) 면역친화성 크로마토그래피에 의한 플라스미노겐 활성화제 억제제 2의 정제방법
KR910011280A (ko) 알칼리성 포스파타제의 정제방법